Drug Type Trispecific killer cell engager (TriKE) |
Synonyms |
Target |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors), CD16a antagonists(Low affinity immunoglobulin gamma Fc region receptor III-A antagonists), NCR3 agonists(natural cytotoxicity triggering receptor 3 agonists) + [3] |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Preclinical | US | - | |
Hematologic Neoplasms | Preclinical | US | - |